Survival rates for many cancers have improved due to new treatments and earlier detection. Yet cases of some cancers, such as ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

Xtandi, Astellas’ roughly $6 billion prostate cancer juggernaut by annual sales, is set to lose U.S. patent protection in ...

HIGHLIGHTSFollowing an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review ...

The latest edition of an annual report finds new cases continue to rise and outcomes have worsened for some cancers.

Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function ...

St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programmeThe patients received Lutetium (177Lu) rhPSMA-10.1 Injections at ...

Researchers found better detection, treatment and decreased smoking have been immensely helpful in reducing deaths due to ...

New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...

Though the findings are positive overall, survival increases since the mid-1990s are especially notable for more fatal ...

But even these patients benefit from advances against cancer, the report said. Five-year survival rates have increased since ...

Adams had reportedly been receiving end-of-life care for the past week, just over six months after he announced his prostate ...